These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 18548464)

  • 1. Nonclinical pharmacokinetics of BMS-292655, a water-soluble prodrug of the antifungal ravuconazole.
    Knipe JO; Mosure KW
    Biopharm Drug Dispos; 2008 Jul; 29(5):270-9. PubMed ID: 18548464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphonooxymethyl prodrugs of the broad spectrum antifungal azole, ravuconazole: synthesis and biological properties.
    Ueda Y; Matiskella JD; Golik J; Connolly TP; Hudyma TW; Venkatesh S; Dali M; Kang SH; Barbour N; Tejwani R; Varia S; Knipe J; Zheng M; Mathew M; Mosure K; Clark J; Lamb L; Medin I; Gao Q; Huang S; Chen CP; Bronson JJ
    Bioorg Med Chem Lett; 2003 Nov; 13(21):3669-72. PubMed ID: 14552754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Species dependent esterase activities for hydrolysis of an anti-HIV prodrug glycovir and bioavailability of active SC-48334.
    Cook CS; Karabatsos PJ; Schoenhard GL; Karim A
    Pharm Res; 1995 Aug; 12(8):1158-64. PubMed ID: 7494828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits.
    Groll AH; Mickiene D; Petraitis V; Petraitiene R; Kelaher A; Sarafandi A; Wuerthwein G; Bacher J; Walsh TJ
    J Antimicrob Chemother; 2005 Nov; 56(5):899-907. PubMed ID: 16172108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic, intestinal, renal, and plasma hydrolysis of prodrugs in human, cynomolgus monkey, dog, and rat: implications for in vitro-in vivo extrapolation of clearance of prodrugs.
    Nishimuta H; Houston JB; Galetin A
    Drug Metab Dispos; 2014 Sep; 42(9):1522-31. PubMed ID: 24994071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.
    Prueksaritanont T; Gorham LM; Ellis JD; Fernandez-Metzler C; Deluna P; Gehret JR; Strong KL; Hochman JH; Askew BC; Duggan ME; Gilbert JD; Lin JH; Vyas KP
    Drug Metab Dispos; 1996 Nov; 24(11):1263-71. PubMed ID: 8937862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
    Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
    Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydrochloride).
    Midgley I; Fitzpatrick K; Taylor LM; Houchen TL; Henderson SJ; Wright SJ; Cybulski ZR; John BA; McBurney A; Boykin DW; Trendler KL
    Drug Metab Dispos; 2007 Jun; 35(6):955-67. PubMed ID: 17360833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist.
    Vachharajani NN; Yeleswaram K; Boulton DW
    J Pharm Sci; 2003 Apr; 92(4):760-72. PubMed ID: 12661062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Penetration of ravuconazole, a new triazole antifungal, into rat tissues.
    Mikamo H; Yin XH; Hayasaki Y; Shimamura Y; Uesugi K; Fukayama N; Satoh M; Tamaya T
    Chemotherapy; 2002 Mar; 48(1):7-9. PubMed ID: 11901249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2.
    Marathe P; Tang Y; Sleczka B; Rodrigues D; Gavai A; Wong T; Christopher L; Zhang H
    J Pharm Sci; 2010 Aug; 99(8):3579-93. PubMed ID: 20166197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
    Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
    Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Animal pharmacokinetics and interspecies scaling of Ro 25-6833 and related (lactamylvinyl)cephalosporins.
    Richter WF; Heizmann P; Meyer J; Starke V; Lave T
    J Pharm Sci; 1998 Apr; 87(4):496-500. PubMed ID: 9548904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Species-specific, P450- and sulfotransferase-mediated novel ring contraction of a naphthyridine-N-oxide compound in cynomolgus monkey.
    Daniels JS; Espina R; Cao K; Yuan H; Lin J; Diamond S; Johnson B; Rodgers J; Prakash S; Unger S; Christ D; Miwa G; Gan LS; Mutlib A
    Chem Res Toxicol; 2007 Nov; 20(11):1709-17. PubMed ID: 17939741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans.
    Wang H; Rangan VS; Sung MC; Passmore D; Kempe T; Wang X; Thevanayagam L; Pan C; Rao C; Srinivasan M; Zhang Q; Gangwar S; Deshpande S; Cardarelli P; Marathe P; Yang Z
    Biopharm Drug Dispos; 2016 Mar; 37(2):93-106. PubMed ID: 25869904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo evaluation of the metabolism and bioavailability of ester prodrugs of mgs0039 (3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid), a potent metabotropic glutamate receptor antagonist.
    Nakamura M; Kawakita Y; Yasuhara A; Fukasawa Y; Yoshida K; Sakagami K; Nakazato A
    Drug Metab Dispos; 2006 Mar; 34(3):369-74. PubMed ID: 16326817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and antifungal activity of the novel water-soluble prodrug of antifungal triazole CS-758.
    Kagoshima Y; Mori M; Suzuki E; Kobayashi N; Shibayama T; Kubota M; Kamai Y; Konosu T
    Chem Pharm Bull (Tokyo); 2010 Jun; 58(6):794-804. PubMed ID: 20522989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.
    Jung D; Lin L; Jiao H; Cai X; Duan JX; Matteucci M
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):643-54. PubMed ID: 21964906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.